



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 67948

Title: HE -positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report

Reviewer's code: 04761856

Position: Peer Reviewer

Academic degree: MD, MSc

Professional title: Assistant Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: Japan

Manuscript submission date: 2021-05-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-14 03:35

Reviewer performed review: 2021-05-15 13:20

Review time: 1 Day and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This case report is well written structurally and stylistically. The disease subject of the study is a very rare condition and deserves to be published as a case report. I will only suggest one minor revision. Please additionally report your treatment plan for recurrent retroperitoneal lymph node after 24 months of follow-up.